Unclaimed brand
Official HCP site for BRIXADI, the only FDA-approved injectable buprenorphine for opioid use disorder (OUD) that offers weekly and monthly doses. Please see Full Prescribing Information, including Boxed Warning.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#783973
Cosmic
120, 57, 115
305, 36, 35
0, 53, 4, 53
#5FAFC5
Fountain Blue
95, 175, 197
193, 47, 57
52, 11, 0, 23
#3E0D3A
Loulou
62, 13, 58
305, 65, 15
0, 79, 6, 76
BRIXADI is a pioneering brand dedicated to transforming the treatment landscape for opioid use disorder (OUD) through its unique extended-release buprenorphine injection. Designed specifically for healthcare professionals, BRIXADI offers patients a viable solution for managing moderate to severe OUD, catering to those who have either started treatment with a transmucosal buprenorphine product or are already receiving buprenorphine therapy.
Utilizing cutting-edge FluidCrystal® Injection Depot Technology, BRIXADI enables steady buprenorphine release either weekly or monthly, minimizing the peaks and troughs associated with traditional opioid treatments. This novel lipid-based formulation allows for small injection volumes and various subcutaneous sites, ensuring patient comfort and compliance.
BRIXADI is safeguarded under a restricted program known as BRIXADI REMS due to the potential risks of intravenous administration. Comprehensive safety information and supportive resources are provided to patients and providers, emphasizing the importance of combining medication assisted treatment with counseling and psychosocial support for optimal recovery outcomes.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
